Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB101 + EGFR-TKI
- Development stage
- Unknown
- Lead developer
- Precision Biotech Taiwan
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
PB101 is an autologous cell therapy developed by Precision Biotech Taiwan Corp., consisting of natural killer (NK) and natural killer T (NKT) cells. It is being investigated in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, afatinib, or osimertinib, for the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. The therapy aims to leverage the innate anti-tumor activity of NK and NKT cells to enhance the efficacy of standard-of-care EGFR-TKIs and potentially overcome resistance mechanisms in patients with advanced disease. A Phase I clinical study is currently evaluating the safety and tolerability of this combination regimen.
- Other names
- PB101 plus EGFR-TKIPB-101 plus EGFR-TKIPB 101 plus EGFR-TKIPB101 in combination with EGFR-TKIPB-101 in combination with EGFR-TKIPB 101 in combination with EGFR-TKI
02
Targets
Beyond the preview
Go deeper on PB101 + EGFR-TKI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB101 + EGFR-TKI.